BR112017017700A2 - métodos, composições e kits para tratamento do câncer - Google Patents

métodos, composições e kits para tratamento do câncer

Info

Publication number
BR112017017700A2
BR112017017700A2 BR112017017700A BR112017017700A BR112017017700A2 BR 112017017700 A2 BR112017017700 A2 BR 112017017700A2 BR 112017017700 A BR112017017700 A BR 112017017700A BR 112017017700 A BR112017017700 A BR 112017017700A BR 112017017700 A2 BR112017017700 A2 BR 112017017700A2
Authority
BR
Brazil
Prior art keywords
kits
compositions
cancer treatment
treatment methods
gffr3
Prior art date
Application number
BR112017017700A
Other languages
English (en)
Portuguese (pt)
Inventor
Holash Jocelyn
Lau Stephen
Original Assignee
Bioclin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioclin Therapeutics Inc filed Critical Bioclin Therapeutics Inc
Publication of BR112017017700A2 publication Critical patent/BR112017017700A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112017017700A 2015-02-19 2016-02-19 métodos, composições e kits para tratamento do câncer BR112017017700A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562118350P 2015-02-19 2015-02-19
US201562150235P 2015-04-20 2015-04-20
PCT/US2016/018634 WO2016134234A1 (en) 2015-02-19 2016-02-19 Methods, compositions, and kits for treatment of cancer

Publications (1)

Publication Number Publication Date
BR112017017700A2 true BR112017017700A2 (pt) 2018-07-31

Family

ID=56689191

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017017700A BR112017017700A2 (pt) 2015-02-19 2016-02-19 métodos, composições e kits para tratamento do câncer

Country Status (12)

Country Link
US (1) US20160243228A1 (enrdf_load_stackoverflow)
EP (1) EP3258966A4 (enrdf_load_stackoverflow)
JP (2) JP6774421B2 (enrdf_load_stackoverflow)
KR (1) KR20170137717A (enrdf_load_stackoverflow)
CN (1) CN107635583A (enrdf_load_stackoverflow)
AU (2) AU2016219917B2 (enrdf_load_stackoverflow)
BR (1) BR112017017700A2 (enrdf_load_stackoverflow)
CA (1) CA2976638A1 (enrdf_load_stackoverflow)
IL (1) IL253979B (enrdf_load_stackoverflow)
MX (1) MX2017010595A (enrdf_load_stackoverflow)
SG (1) SG11201706727XA (enrdf_load_stackoverflow)
WO (1) WO2016134234A1 (enrdf_load_stackoverflow)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1006448B1 (pt) 2009-03-25 2021-08-17 Genentech, Inc Anticorpo antagonista anti-fgfr3, anticorpo monoclonal, polinucleotídeo, vetor, micro­organismo transgênico, método para produção de um anticorpo anti-fgfr3, formulação farmacêutica e usos do anticorpo antagonista anti-fgfr3
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
AU2015238301B2 (en) 2014-03-26 2020-06-25 Astex Therapeutics Ltd Combinations
WO2015144808A1 (en) 2014-03-26 2015-10-01 Astex Therapeutics Ltd Combinations of an fgfr inhibitor and an igf1r inhibitor
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
AU2016328693B2 (en) 2015-09-23 2021-03-11 Janssen Pharmaceutica Nv Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
DK3353177T3 (da) 2015-09-23 2020-08-24 Janssen Pharmaceutica Nv Tricykliske heterocykler til behandling af cancer
JP2020506945A (ja) * 2017-02-06 2020-03-05 レーニア セラピューティクス インコーポレイテッド がんの治療のための方法、組成物及びキット
CN108440673B (zh) * 2018-04-08 2021-08-17 海南医学院 Fc融合蛋白PD1/FGFR1及其应用
US20200277387A1 (en) * 2019-03-01 2020-09-03 Rainier Therapeutics, Inc. Methods and compositions for treating cancer
BR112021017405A2 (pt) * 2019-06-03 2021-12-07 Fusion Pharmaceuticals Inc Métodos e composições para tratar câncer
PH12022550743A1 (en) * 2019-09-26 2024-06-19 Janssen Pharmaceutica Nv Use of fgfr inhibitors in fgfr-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings
AR121643A1 (es) * 2020-03-23 2022-06-22 Fusion Pharmaceuticals Inc Radioinmunoconjugados dirigidos a fgfr3 y usos de estos
CA3189470A1 (en) 2020-08-21 2022-02-24 Yves SABBAGH Fgfr3 antibodies and methods of use
TW202233185A (zh) * 2020-10-28 2022-09-01 日商衛材R&D企管股份有限公司 腫瘤治療用醫藥組合物
US20240247069A1 (en) 2023-01-13 2024-07-25 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR073770A1 (es) * 2008-10-20 2010-12-01 Imclone Llc Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
BRPI1006448B1 (pt) * 2009-03-25 2021-08-17 Genentech, Inc Anticorpo antagonista anti-fgfr3, anticorpo monoclonal, polinucleotídeo, vetor, micro­organismo transgênico, método para produção de um anticorpo anti-fgfr3, formulação farmacêutica e usos do anticorpo antagonista anti-fgfr3
WO2012088266A2 (en) * 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
AR091649A1 (es) * 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
RU2015102194A (ru) * 2012-07-27 2016-09-20 Дженентек, Инк. Способы лечения связанных с fgfr3 состояний
HRP20201404T1 (hr) * 2013-07-16 2020-11-27 F. Hoffmann - La Roche Ag Postupci liječenja raka primjenom pd-1 osno vezujućeg antagonista i inhibitora tigita

Also Published As

Publication number Publication date
AU2022200196A1 (en) 2022-02-10
KR20170137717A (ko) 2017-12-13
JP6774421B2 (ja) 2020-10-21
WO2016134234A1 (en) 2016-08-25
SG11201706727XA (en) 2017-09-28
EP3258966A4 (en) 2018-07-25
EP3258966A1 (en) 2017-12-27
AU2022200196B2 (en) 2025-04-10
NZ735243A (en) 2024-11-29
MX2017010595A (es) 2018-11-12
CA2976638A1 (en) 2016-08-25
JP7122357B2 (ja) 2022-08-19
US20160243228A1 (en) 2016-08-25
JP2018507220A (ja) 2018-03-15
IL253979B (en) 2021-06-30
AU2016219917A1 (en) 2017-09-07
IL253979A0 (en) 2017-10-31
CN107635583A (zh) 2018-01-26
JP2021020909A (ja) 2021-02-18
AU2016219917B2 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
BR112017017700A2 (pt) métodos, composições e kits para tratamento do câncer
CL2021000084A1 (es) Inhibidores de pd-1/pd-l1
CL2018001134A1 (es) Composiciones y métodos para inhibir la actividad arginasa
BR112016017256A2 (pt) combinação de um antagonista de pd-1 e um inibidor de vegfr para o tratamento de câncer
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
MX2017016868A (es) Composiciones y metods para inhibir actividad de arginasa.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
DOP2016000153A (es) Anticuerpos y fragmentos anti-vista
MX391470B (es) Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
MX379270B (es) Composiciones que comprenden cepas bacterianas.
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
MX2016010080A (es) Combinacion de un antagonista de muerte programada-1 y un inhibidor de indolamina 2,3-dioxigenasa 1 para el tratamiento del cancer.
MX376078B (es) Combinación de un antagonista de pd -1 y dinaciclib para usarse en el tratamiento de cáncer.
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
MX2017010773A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte progamada 1 (pd-l1) para el tratamiento de cancer.
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112016022667A2 (pt) Uso de álcool d-pantotenílico para a fabricação de inibidor de melanogênese e método de branquear a pele
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
MX2017001490A (es) Combinaciones de farmacos para tratar mieloma multiple.
BR112017008799A2 (pt) composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
MX382996B (es) Inhibidores de pcna
MX2017011018A (es) Inhibicion de la actividad de olig2.

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: BIOCLIN THERAPEUTICS, INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25C Requirement related to requested transfer of rights

Owner name: BIOCLIN THERAPEUTICS, INC. (US)

Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 870200115552 DE 11/09/2020, E NECESSARIO ESCLARECER A DIVERGENCIA ENTRE O NOME DA EMPRESA TITULAR DO PEDIDO E O NOME DA EMPRESA CEDENTE.

B25D Requested change of name of applicant approved

Owner name: RAINIER THERAPEUTICS, INC. (US)

B25A Requested transfer of rights approved

Owner name: FUSION PHARMACEUTICALS INC. (CA)

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]